» Articles » PMID: 30538129

High-mobility Group Box 1 Links Sensing of Reactive Oxygen Species by Huntingtin to Its Nuclear Entry

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2018 Dec 13
PMID 30538129
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Huntington's disease (HD) is a neurodegenerative, age-onset disorder caused by a CAG DNA expansion in exon 1 of the gene, resulting in a polyglutamine expansion in the huntingtin protein. Nuclear accumulation of mutant huntingtin is a hallmark of HD, resulting in elevated mutant huntingtin levels in cell nuclei. Huntingtin is normally retained at the endoplasmic reticulum via its N17 amphipathic α-helix domain but is released by oxidation of Met-8 during reactive oxygen species (ROS) stress. Huntingtin enters the nucleus via an importin β1- and 2-dependent proline-tyrosine nuclear localization signal (PY-NLS), which has a unique intervening sequence in huntingtin. Here, we have identified the high-mobility group box 1 (HMGB1) protein as an interactor of the intervening sequence within the PY-NLS. Nuclear levels of HMGB1 positively correlated with varying levels of nuclear huntingtin in both HD and normal human fibroblasts. We also found that HMGB1 interacts with the huntingtin N17 region and that this interaction is enhanced by the presence of ROS and phosphorylation of critical serine residues in the N17 region. We conclude that HMGB1 is a huntingtin N17/PY-NLS ROS-dependent interactor, and this protein bridging is essential for relaying ROS sensing by huntingtin to its nuclear entry during ROS stress. ROS may therefore be a critical age-onset stress that triggers nuclear accumulation of mutant huntington in Huntington's disease.

Citing Articles

Pathological role of RAGE underlying progression of various diseases: its potential as biomarker and therapeutic target.

Sarkar S Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39589529 DOI: 10.1007/s00210-024-03595-6.


Pathophysiological role of high mobility group box-1 signaling in neurodegenerative diseases.

Kumar V, Kumar P Inflammopharmacology. 2024; 33(2):703-727.

PMID: 39546221 DOI: 10.1007/s10787-024-01595-9.


Mechanistic insights on the role of Nrf-2 signalling in Huntington's disease.

Sharma V, Sharma P, Singh T Neurol Sci. 2024; 46(2):593-604.

PMID: 39392523 DOI: 10.1007/s10072-024-07802-3.


Ferroptosis regulation through Nrf2 and implications for neurodegenerative diseases.

Xiang Y, Song X, Long D Arch Toxicol. 2024; 98(3):579-615.

PMID: 38265475 PMC: 10861688. DOI: 10.1007/s00204-023-03660-8.


High Mobility Group Box 1 Protein: A Plausible Therapeutic Molecular Target in Parkinson's Disease.

Goyal A, Agrawal A, Dubey N, Verma A Curr Pharm Biotechnol. 2023; 25(8):937-943.

PMID: 37670710 DOI: 10.2174/1389201025666230905092218.


References
1.
Caron N, Desmond C, Xia J, Truant R . Polyglutamine domain flexibility mediates the proximity between flanking sequences in huntingtin. Proc Natl Acad Sci U S A. 2013; 110(36):14610-5. PMC: 3767516. DOI: 10.1073/pnas.1301342110. View

2.
Dishinger J, Kee H, Jenkins P, Fan S, Hurd T, Hammond J . Ciliary entry of the kinesin-2 motor KIF17 is regulated by importin-beta2 and RanGTP. Nat Cell Biol. 2010; 12(7):703-10. PMC: 2896429. DOI: 10.1038/ncb2073. View

3.
Thompson L, Aiken C, Kaltenbach L, Agrawal N, Illes K, Khoshnan A . IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J Cell Biol. 2009; 187(7):1083-99. PMC: 2806289. DOI: 10.1083/jcb.200909067. View

4.
Brouillet E, Jenkins B, Hyman B, Ferrante R, Kowall N, Srivastava R . Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J Neurochem. 1993; 60(1):356-9. DOI: 10.1111/j.1471-4159.1993.tb05859.x. View

5.
Vezzoli M, Castellani P, Campana L, Corna G, Bosurgi L, Manfredi A . Redox remodeling: a candidate regulator of HMGB1 function in injured skeletal muscle. Ann N Y Acad Sci. 2010; 1209:83-90. DOI: 10.1111/j.1749-6632.2010.05748.x. View